To date there are no approved anti-EGFR antibodies for ovarian cancer, and while there was one clinical trial involving panitumumab (Vectibix) in combination with AMG 706 and gemcitabine-cisplatin in patients with advanced cancers (including ovarian), this trial was terminated. This evidence concerns the gene EGFR and ovarian carcinoma.